Collegium Pharmaceutical, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Collegium Pharmaceutical, Inc. (COLL) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $717.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2025-02-27
- Collegium Pharmaceutical, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $717.00K, a 36.05% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $527.00K.
- Collegium Pharmaceutical, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $0.00.
- Collegium Pharmaceutical, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was -$11.62M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $717.00K 10-K · filed 2025-02-27 | |
| 2023-12-31 | $527.00K 10-K · filed 2024-02-22 | |
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 | |
| 2020-12-31 | -$11.62M 10-K · filed 2021-02-25 | |
| 2019-12-31 | -$3.00M 10-K · filed 2020-02-27 | |
| 2018-12-31 | $9.92M 10-K · filed 2019-02-27 | |
| 2017-12-31 | -$6.20M 10-K · filed 2019-02-27 | |
| 2016-12-31 | $34.50M 10-K · filed 2018-03-07 | -$34.50M 10-K · filed 2017-03-10 |
| 2015-12-31 | -$10.54M 10-K · filed 2017-03-10 | $10.54M 10-K · filed 2016-03-18 |
| 2014-12-31 | $7.74M 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |